Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy
C Pottier, M Fresnais, M Gilon, G Jérusalem… - Cancers, 2020 - mdpi.com
Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …
Sarcoma treatment in the era of molecular medicine
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …
Although constituting only 1% of all human malignancies, sarcomas represent the second …
[HTML][HTML] Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
PH Deprez, LMG Moons, D OʼToole, R Gincul… - …, 2022 - thieme-connect.com
1 ESGE recommends endoscopic ultrasonography (EUS) as the best tool to characterize
subepithelial lesion (SEL) features (size, location, originating layer, echogenicity, shape) …
subepithelial lesion (SEL) features (size, location, originating layer, echogenicity, shape) …
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, N Abecassis, S Bauer, R Biagini… - Annals of …, 2018 - annalsofoncology.org
Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular
subsets, characterised by a low to very low incidence in all populations. The majority of …
subsets, characterised by a low to very low incidence in all populations. The majority of …
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
E Molinaro, C Romei, A Biagini, E Sabini… - Nature Reviews …, 2017 - nature.com
Anaplastic thyroid carcinoma (ATC) is a rare malignancy, accounting for 1–2% of all thyroid
cancers. Although rare, ATC accounts for the majority of deaths from thyroid carcinoma. ATC …
cancers. Although rare, ATC accounts for the majority of deaths from thyroid carcinoma. ATC …
Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network
G De Pinieux, M Karanian, F Le Loarer, S Le Guellec… - PLoS …, 2021 - journals.plos.org
Background Since 2010, nationwide networks of reference centers for sarcomas
(RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas …
(RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas …
[HTML][HTML] Surgery in reference centers improves survival of sarcoma patients: a nationwide study
JY Blay, C Honore, E Stoeckle, P Meeus, M Jafari… - Annals of …, 2019 - Elsevier
Background NETSARC (netsarc. org) is a network of 26 sarcoma reference centers with
specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of …
specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of …
Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study
PURPOSE Primary or secondary mutations in KIT or platelet-derived growth factor receptor
alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors …
alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors …
Improving immunotherapy efficacy in soft-tissue sarcomas: A biomarker driven and histotype tailored review
M Roulleaux Dugage, EF Nassif, A Italiano… - Frontiers in …, 2021 - frontiersin.org
Anti-PD-(L) 1 therapies yield a disappointing response rate of 15% across soft-tissue
sarcomas, even if some subtypes benefit more than others. The proportions of TAMs and …
sarcomas, even if some subtypes benefit more than others. The proportions of TAMs and …
Gastrointestinal stromal tumor: challenges and opportunities for a new decade
C Serrano, S George - Clinical Cancer Research, 2020 - AACR
Gastrointestinal stromal tumor (GIST) provides a paradigm to evaluate new molecularly
targeted therapies and to identify structural and functional mechanisms for drug response …
targeted therapies and to identify structural and functional mechanisms for drug response …